STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

News

Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) to participate in 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
-
News

Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) announced the discontinuation of the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer patients. The trial was discontinued due to futility, as it was unlikely to meet its primary endpoints. The safety profile was consistent with previous studies, and investigation for other tumor types will continue. This does not impact the currently approved indication for patients with unresectable or metastatic melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
News

Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024

Rhea-AI Summary
Bristol Myers Squibb (BMY) will release its Q4 2023 results on February 2, 2024, with a conference call for investors and analysts at 8:00 a.m. ET. The live webcast can be accessed at http://investor.bms.com, and materials will be available prior to the call. A replay will also be available on the same website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
conferences earnings
News

Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb

Rhea-AI Summary
Terray Therapeutics (BMY) collaborates with Bristol Myers Squibb to discover and develop small molecule therapeutics against certain disease areas. The collaboration includes upfront payment, milestone payments, and royalties on global net sales of products. Terray will utilize its tNova drug discovery platform to identify small molecule compounds against targets nominated by Bristol Myers Squibb, with Bristol Myers Squibb assuming responsibility for development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
News

Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023

Rhea-AI Summary
Bristol Myers Squibb (BMY) announced the results of two early studies evaluating combinations of golcadomide with R-CHOP and rituximab in non-Hodgkin lymphomas at the 2023 American Society of Hematology (ASH) Annual Meeting. The studies showed promising activity and combinability of golcadomide in patients with previously untreated aggressive B-cell lymphoma and heavily pretreated patients with diffuse large B-cell lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
News

Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) presents updated results from multiple myeloma research pipeline at ASH, demonstrating deepening responses and durable outcomes for BMS-986393, mezigdomide, and alnuctamab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
News

Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3

Rhea-AI Summary
Bristol Myers Squibb (BMY) and 2seventy bio, Inc. (TSVT) announced results from the final progression-free survival (PFS) analysis of KarMMa-3, a Phase 3 study evaluating Abecma in adults with relapsed and refractory multiple myeloma. Abecma maintained a 51% reduction in risk of disease progression or death with a median PFS of 13.8 months compared to 4.4 months for standard regimens. The complete response rate was 44% vs. 5% for standard regimens. Abecma demonstrated deep and durable responses in newly-diagnosed multiple myeloma with a 77% complete response rate and no new safety signals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
News

SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1

Rhea-AI Summary
SystImmune (BL-B01D1) and Bristol Myers Squibb (BMY) have entered into an exclusive license and collaboration agreement for the development and commercialization of BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate. The companies will jointly develop and commercialize BL-B01D1 in the United States, with SystImmune retaining exclusive rights in Mainland China and Bristol Myers Squibb gaining an exclusive license in the rest of the world. The financial highlights of the agreement include an $800 million upfront payment to SystImmune and up to $7.1 billion in contingent payments based on certain milestones, making the total potential consideration up to $8.4 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
News

Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

Rhea-AI Summary
Bristol Myers Squibb (BMY) announced the primary analysis results from TRANSCEND FL, where 95.7% of patients with high-risk relapsed or refractory follicular lymphoma (FL) treated with Breyanzi achieved a complete response, with a manageable safety profile. Additionally, long-term follow-up data from TRANSCEND CLL 004 continue to demonstrate deep and durable complete responses and a manageable and predictable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
News

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023

Rhea-AI Summary
Bristol Myers Squibb (BMY) announced updated results from the primary analysis of the Phase 3 COMMANDS trial, comparing Reblozyl® (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS). Reblozyl demonstrated superior efficacy and durability compared to ESAs and is under review with the European Commission, with priority review approval by the United States Food and Drug Administration for the treatment of anemia in ESA-naïve adult patients with very low- to intermediate-risk MDS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
clinical trial

FAQ

What is the current stock price of Bristol-Myers Squibb Co. (BMY)?

The current stock price of Bristol-Myers Squibb Co. (BMY) is $57.76 as of December 24, 2024.

What is the market cap of Bristol-Myers Squibb Co. (BMY)?

The market cap of Bristol-Myers Squibb Co. (BMY) is approximately 117.1B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#108 Ranked by Market Cap
#719 Ranked by Dividends

BMY Stock Data

117.15B
2.03B
0.12%
78.46%
1.27%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
PRINCETON